Directorio

This study will last about two to a little over two years from the day you sign up until your last checkup. If the doctors decide you are a good fit after the first tests, you will have surgery to place the ARCIM System inside your body. After the surgery, you will have many checkups over the next two years so the study team can see how well the treatment is working for you. During these visits, the team will adjust the device to make sure it works well for your daily life. You will also answer questions and take part in health checkups during clinic visits. Some visits will be done by email or phone. Altogether, you will spend about fifteen days in person at the clinic during the whole study. The study team will be there to help and guide you at every step.

We are doing this study to learn more about how brain cell activity guides memory and navigation.

The Endometrial Cancer Molecularly Targeted Therapy Consortium is a multi-institutional alliance that is developing a cancer data and tissue repository. The information in this repository will be used to better understand tumor alterations and cancer biomarkers that can help us develop new therapies and potentially improve survival outcomes for women with endometrial cancer.

We are doing this study to keep tabs on the performance of a medical device called TVT Exact. This device is used to help control stress urinary incontinence. We want to know how well this device works long-term in Duke patients who elected to use it.

We are doing this study to find out if an experimental drug called XC001 (the study drug) is an effective option for people who have angina that is caused by coronary artery disease. We want to know if the study drug can provide relief when common, approved therapies have failed to do so. The study drug is made using an adenovirus (one of the causes of the common cold). The adenovirus in the study drug is genetically altered so it is able to deliver a protein called VEGF (vascular endothelial growth factor) to the heart and potentially spur the growth of new blood vessels.

In this study, people will get a new kind of eye transplant. They'll be randomly chosen (like flipping a coin) to get either a special treated cornea or a regular one. Doctors will check on them for 2 years after the transplant to see how they're doing and to watch for any side effects.